Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial

被引：0
|
作者：
Dimitriadis, Georgios K. [1 ]
Batterham, Rachel [2 ]
Bhatta, Meena [3 ]
Holst-Hansen, Thomas [3 ]
Kandler, Kristian [3 ]
Rigas, Georgia [4 ]
Garvey, W. Timothy [5 ]
机构：
[1] Kings Coll London, London, England
[2] UCL, Div Med, Obes Res Ctr, London, England
[3] Novo Nordisk AS, Soborg, Denmark
[4] St George Private Hosp, Dept Bariatr Metab Surg, Kogarah, NSW, Australia
[5] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA
来源：
OBESITY SURGERY | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [21] Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Abdelmalek, Manal F.
    Armstrong, Matthew J.
    Jara, Maximilian
    Kjaer, Mette Skalshoi
    Krarup, Niels
    Lawitz, Eric
    Ratziu, Vlad
    Sanyal, Arun J.
    Schattenberg, Jorn M.
    Newsome, Philip N.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : 511 - 522
  • [22] Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial
    McGowan, Barbara M.
    Houshmand-Oeregaard, Azadeh
    Laursen, Peter Norkjaer
    Zeuthen, Niels
    Baker-Knight, James
    OBESITY, 2023, 31 (04) : 990 - 999
  • [23] Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial
    Kolotkin, Ronette L.
    Jeppesen, Ole Kleist
    Baker-Knight, James
    Lee, Sang Yeoup
    Tokita, Asako
    Kadowaki, Takashi
    CLINICAL OBESITY, 2023, 13 (04)
  • [24] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
    McCrimmon, Rory J.
    Catarig, Andrei-Mircea
    Frias, Juan P.
    Lausvig, Nanna L.
    le Roux, Carel W.
    Thielke, Desiree
    Lingvay, Ildiko
    DIABETOLOGIA, 2020, 63 (03) : 473 - 485
  • [25] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
    Rory J. McCrimmon
    Andrei-Mircea Catarig
    Juan P. Frias
    Nanna L. Lausvig
    Carel W. le Roux
    Desirée Thielke
    Ildiko Lingvay
    Diabetologia, 2020, 63 : 473 - 485
  • [26] Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes: STEP 2 post-hoc analysis
    Deanfield, J. E.
    Davies, M.
    Garvey, W. T.
    Jeppesen, O. K.
    Khalid, U.
    Kosiborod, M.
    Kushner, R. F.
    Laursen, P. N.
    Rubino, D. M.
    Verma, S.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 249 - 249
  • [27] Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Abdelmalek, Manal F.
    Armstrong, Matthew
    Jara, Maximilian
    Kjaer, Mette
    Krarup, Niels
    Lawitz, Eric
    Ratziu, Vlad
    Sanyal, Arun
    Schattenberg, Joern
    Newsome, Philip N.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S10 - S10
  • [28] Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis
    Kushner, Robert F.
    Davies, Melanie J.
    Deanfield, John
    Garvey, W. Timothy
    Jeppesen, Ole
    Khalid, Usman
    Kosiborod, Mikhail N.
    Laursen, Peter N.
    Rubino, Domenica
    Verma, Subodh
    DIABETES, 2021, 70
  • [29] Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
    Buse, John B.
    Christensen, Helene Nordahl
    Harty, Brian J.
    Mitchell, Julie
    Soule, Benjamin P.
    Zacherle, Emily
    Cziraky, Mark
    Willey, Vincent J.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (03)
  • [30] Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity
    Wilkinson, Lua
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Batterham, Rachel L.
    Garvey, W. Timothy
    OBESITY, 2023, 31 (09) : 2249 - 2259
12345